Notable
XS411 Cell Injection · Primary Parkinson's Disease
Primary completion pushed from Apr 30, 2026 to Jul 2027
Also in this update: Primary endpoint(s) modified; Phase changed: Phase 1 → Phase 1/2
XellSmart Therapeutics (Shanghai) Co., Ltd.Phase 1/2 NCT07080775 Registry history of NCT07080775 on ClinicalTrials.gov (opens the registry)